MétaCan
Menu
Back to cohort
Record W4411535590 · doi:10.1080/14796678.2025.2513805

Long-term safety and effectiveness of evinacumab in people with homozygous familial hypercholesterolemia: a plain language summary

2025· article· en· W4411535590 on OpenAlexaffabout
Daniel Gaudet, Susanne Greber‐Platzer, Laurens F. Reeskamp, Gabriella Iannuzzo, Robert S. Rosenson, Samir Saheb, Claudia Stefanutti, Erik S.G. Stroes, Albert Wiegman, Traci Turner, Shazia Ali, Poulabi Banerjee, Jennifer McGinniss, Alpana Waldron, Richard T. De George, Xue-Qiao Zhao, Robert Pordy, Éric Bruckert, Frederick J. Raal

Bibliographic record

VenueFuture Cardiology · 2025
Typearticle
Languageen
FieldMedicine
TopicLipoproteins and Cardiovascular Health
Canadian institutionsUniversité du Québec à Chicoutimi
FundersServierNovo NordiskArgenxAmryt PharmaFresenius Medical Care North AmericaAmarin CorporationMylanIonis PharmaceuticalsAbbott LaboratoriesRegeneron PharmaceuticalsEsperion TherapeuticsUltragenyx PharmaceuticalBristol-Myers SquibbEli Lilly and CompanyAstraZenecaAmgenVifor PharmaPfizerDaiichi Sankyo EuropeSilence TherapeuticsKowa CompanySanofi
KeywordsMedicineFamilial hypercholesterolemiaTerm (time)Plain languagePediatricsInternal medicineIntensive care medicineLinguisticsCholesterol

Abstract

fetched live from OpenAlex

Plain Language SummaryWhat is this summary about?This summary explains the results of a study looking at the long-term effects of a treatment called evinacumab. This study included people aged over 12 years with homozygous familial hypercholesterolemia, also known as HoFH. HoFH is a rare genetic disorder that makes the liver less able to remove excess ‘bad’ cholesterol (called low-density lipoprotein cholesterol, or LDL-C) from the body. LDL-C is considered ‘bad’ cholesterol because it increases the risk of heart disease and stroke. High levels of LDL-C increase the risk of developing serious heart problems early in life. Treatment options for lowering LDL-C often do not work very well for people with HoFH. Evinacumab is a medicine that is approved for the treatment of HoFH as an add-on to other therapies that lower LDL-C. The effect of evinacumab on heart problems such as heart attacks, stroke, or death is not known. In the UK, evinacumab is approved for people with HoFH aged 6 months and above. In Canada and the USA, evinacumab is approved for people with HoFH aged 5 years and above. In the European Union/European Economic Area, evinacumab is approved for people with HoFH aged 6 months and above. In Japan, evinacumab is approved for all ages of people with HoFH. More recently, evinacumab has also been approved in Brazil and Israel.What were the results?People with HoFH who took part in the study were treated with evinacumab every 4 weeks for up to 44 months.After 6 months of treatment, LDL-C levels were almost 44% lower than when people started the study.Treatment-emergent adverse events, also called TEAEs, were reported by 80% of people in the study but most of these were mild (23.3%) or moderate (41.4%) in severity. The most commonly reported side effects which happened during the study were common cold, COVID-19, headache, flu-like illness, general pain, back pain, nausea, and cough. The study researchers determined that most of these reported side effects (91%) were not related to the use of evinacumab.No serious TEAEs were considered related to evinacumab treatment. Nearly all of the people (97%) could continue with the study treatment and, based on this, the researchers concluded that evinacumab was generally well tolerated.What do the results mean?This study showed that evinacumab lowered ‘bad’ cholesterol in people with HoFH, and that this result lasted for a long period of time.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.030
Threshold uncertainty score0.542

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.003
GPT teacher head0.243
Teacher spread0.240 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueFuture CardiologySame topicLipoproteins and Cardiovascular HealthFrench-language works237,207